Switch to:
More From Other Websites
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 28 2016
How Did XBI’s Large Caps Perform? Apr 28 2016
Alexion (ALXN) Lags Q1 Earnings & Revenues, Revises View Apr 28 2016
Sanofi launches $9.3 billion fight for U.S. cancer firm Medivation Apr 28 2016
Sanofi launches $9.3 bln fight for U.S. cancer firm Medivation Apr 28 2016
Sanofi launches $9.3 bln fight for U.S. cancer firm Medivation Apr 28 2016
Alexion (ALXN) Misses on Q1 Earnings and Revenues Apr 28 2016
[$$] Alexion Profit Declines but Revenue Rises Apr 28 2016
Q1 2016 Alexion Pharmaceuticals Inc Earnings Release - Before Market Open Apr 28 2016
Alexion misses Street 1Q forecasts Apr 28 2016
Alexion misses Street 1Q forecasts Apr 28 2016
6:47 am Alexion Pharma misses by $0.02, misses on revs; guides FY16 revs below consensus Apr 28 2016
Alexion Reports First Quarter 2016 Results Apr 28 2016
Alexion Reports First Quarter 2016 Results Apr 28 2016
Alexion (ALXN) Q1 Earnings: What's in Store for the Stock? Apr 26 2016
4 Biotechs That Will Escape Weak Seasonal Trends for the Sector Apr 26 2016
Why Has Teva Pharmaceutical Targeted Orphan Diseases? Apr 14 2016
Analyzing XLV: Why Did It Remain Stable and Positive? Apr 13 2016
Alexion Pharmaceuticals to Report First Quarter 2016 Results on Thursday, April 28, 2016 Apr 12 2016
Alexion Pharmaceuticals to Report First Quarter 2016 Results on Thursday, April 28, 2016 Apr 12 2016
Alexion Pharma (ALXN) Stock Receives 'Market Perform' Rating at BMO Capital Apr 07 2016
Is Biotech Back? Apr 07 2016
Alexion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ALXN) : April 5, 2016 Apr 05 2016
Under the Radar: Hudson's Bay & biotech Apr 05 2016
Alexion Pharmaceuticals’ New Data from Phase 2 Trial of Strensiq Apr 05 2016
Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALXN-US :... Apr 04 2016
Data Presented at ENDO 2016 Show Sustained Improvements in Survival Rates, Bone Healing, Respiratory... Apr 04 2016
Kanuma® (sebelipase alfa) Receives Marketing Approval in Japan for Treatment of Patients with... Mar 28 2016
UK cost agency queries value of $700,000-a-year Alexion drug Feb 18 2016
UK cost agency queries value of $700,000-a-year Alexion drug Feb 17 2016
Alexion beats 4Q profit forecasts Feb 03 2016
Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2015 Results on Wednesday, February... Jan 20 2016
Alexion to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 04 2016
Alexion Highlights Innovative Rare Disease Portfolio at Investor Day Meeting Dec 10 2015
Alexion to Highlight Innovative Rare Disease Portfolio at Investor Day Meeting Dec 10 2015
FDA Approves Kanuma™ (sebelipase alfa) for the Treatment of Patients with Lysosomal Acid Lipase... Dec 08 2015
Alexion's $550,000 bone drug too expensive for Britain Dec 02 2015
Alexion to Highlight Robust Rare Disease Pipeline at Investor Day Nov 19 2015
Germany, U.S. in hot pursuit of "messenger" drug molecules Nov 12 2015
Alexion Reports Third Quarter 2015 Results Oct 29 2015
Alexion reports 3Q loss Oct 29 2015
FDA Approves Strensiq™ (asfotase alfa) for Treatment of Patients with Perinatal-, Infantile- and... Oct 23 2015
Alexion Pharmaceuticals to Report Third Quarter 2015 Results on Thursday, October 29, 2015 Oct 12 2015
Alexion Announces Presentations at ASN 2015, Including a Long-Term Follow-Up Study of Soliris®... Oct 02 2015
Alexion Announces Presentations at 2015 American Society for Bone and Mineral Research Annual... Sep 16 2015
New England Journal of Medicine (NEJM) Publishes Pivotal Phase 3 Data on Kanuma™ (sebelipase alfa)... Sep 09 2015
Alexion Receives Notification of PDUFA Date Extension for Kanuma™ (sebelipase alfa) Sep 04 2015
Alexion to Present at the 2015 Morgan Stanley Global Healthcare Conference Sep 03 2015
Alexion gets EU approval for drug acquired in Synageva deal Sep 01 2015
Alexion gets EU approval for drug acquired in Synageva deal Sep 01 2015
European Commission Grants Marketing Authorization for Strensiq™ (asfotase alfa) for the Treatment... Sep 01 2015
European Commission Grants Marketing Authorization for Kanuma™ (sebelipase alfa) for the Treatment... Sep 01 2015
Alexion tops Street 2Q forecasts Jul 30 2015
Alexion to bolster rare disease offering with $8.4 billion deal May 06 2015
US stocks drop on jobs data, Yellen's warning on values May 06 2015
US stocks drop on jobs data, Yellen's warning on values May 06 2015
Deals of the day- Mergers and acquisitions May 06 2015
Alexion to bolster rare disease offering with $8.4 billion deal May 06 2015
Alexion Pharma to pay $8.4 billion for Synageva BioPharma May 06 2015
US stocks drop in volatile trade on weak jobs data May 06 2015
Alexion to buy Synageva BioPharma in $8.4 billion deal May 06 2015
US stocks drop in volatile trade on weak jobs data May 06 2015
US stocks rise on big biopharma merger May 06 2015
US stocks rise on big biopharma merger May 06 2015
Alexion misses 1Q profit forecasts Apr 23 2015
Alexion beats Street 4Q forecasts Jan 29 2015
Alexion Pharma co-founder Squinto to retire Nov 10 2014
Alexion tops Street 3Q forecasts Oct 23 2014
US STOCKS-Wall St rallies, S&P back above 14-day moving average Sep 24 2014


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK